Loading clinical trials...
Loading clinical trials...
Phase 1 Study to Evaluate [18F]MNI-1216 ([18F]ACI-12589) as a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain of Patients With Suspected Alpha-synuclein Pathology Compared With Healthy Volunteers
Conditions
Interventions
[18F]MNI-1216
Locations
1
United States
Invicro
New Haven, Connecticut, United States
Start Date
December 24, 2020
Primary Completion Date
November 26, 2024
Completion Date
November 26, 2024
Last Updated
February 19, 2025
NCT07330258
NCT06508801
NCT07384429
NCT07310264
NCT02119611
NCT04246437
Lead Sponsor
Invicro
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions